@ShahidNShah
Medtronic's MiniMed 770G Scores FDA Clearance for Kids and Adults
The MiniMed 780G was trialed on 39 adolescents and 118 adults with Type 1 Diabetes. Participants used the system for two 45-day periods with different blood glucose target points. The study found that the participant's overall time in range was 75%.
According to an FDA release, the company also conducted clinical trials that included 46 children between 2 and 6 and found no serious adverse events. However, the agency will require Medtronic to conduct post-market research on children in that age range.
Medtronic’s interest in the diabetes space isn’t limited to close loop systems. This summer, Medtronic announced its plans to buy Companion Medical, which is best known for making the InPen, an insulin pen that integrates a companion app, for an undisclosed sum.
Read on mobihealthnews.com
Continue reading at mobihealthnews.com
Next Article
-
CMS agrees to cover 'breakthrough' medical devices
Medicare patients will have coverage for medical devices the FDA designates as breakthrough technology under a proposed rule released this morning. Once the Medicare Coverage of Innovative Technology …
Posted Sep 2, 2020cmsmedtech